AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Allegro Ophthalmics to Present the Results of Its ALG-1007 Ex-U.S. Trial for Dry Eye Disease at the 2019 ASCRS•ASOA Annual Meeting

April 30, 2019

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Apr 30, 2019--Following last week’s news that the company is expanding its pipeline into dry eye and has created a new Cornea Scientific Advisory Board (Cornea SAB), Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced that the results of its ALG-1007 ex-U.S. proof-of-concept clinical trial for the treatment of dry eye disease (DED) will be presented during the 2019 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS•ASOA) Annual Meeting being held May 3-7 in San Diego, CA.

On Thursday, May 2, Allegro’s President and CEO Vicken Karageozian, M.D., will provide an overview on the company’s vision moving forward into other ocular indications at the Ophthalmology Innovation Summit (OIS). Then on Monday, May 6, Eric D. Donnenfeld, M.D., will present full study results of the ALG-1007 ex-U.S. proof-of-concept clinical trial for DED at ASCRS•ASOA.

The expansion into front-of-the-eye indications bolsters Allegro’s existing anti-integrin portfolio, which includes risuteganib (Luminate®), currently being developed for diabetic macular edema (DME) and intermediate dry age-related macular degeneration (intermediate dry AMD). Pre-clinical and clinical findings of risuteganib convinced the company that it could develop a new anti-integrin compound to treat DED.

“Allegro is excited to share, for the first time, our ex-U.S. proof-of-concept data with the clinical community at ASCRS and OIS,” said Dr. Karageozian. “Allegro is continuously exploring new ways to apply our anti-integrin portfolio to help improve patients’ vision, and ALG-1007 represents our first exploratory drug for the potential treatment of dry eye, a disease that adversely affects millions of Americans.”

The corporate and scientific presentations are scheduled as follows:

Thursday, May 2: 9:45-9:51 AM
Ophthalmology Innovation Summit, Hilton San Diego Bayfront
Addressing the Unmet Need of Ocular Diseases with a Novel Anti-Integrin Portfolio.
Vicken Karageozian, M.D.
Monday, May 6: 1:45-1:50 AM
San Diego Convention Center, Room 1B
A Pilot Study to Evaluate the Safety and Exploratory Efficacy of ALG-1007 Topical Ophthalmic Solution for the Treatment of Dry Eye Disease. Eric D. Donnenfeld, M.D.

All educational content of the ASCRS•ASOA Annual Meeting is planned by its program committee, and ASCRS•ASOA does not endorse, promote, approve, or recommend the use of any products, devices, or services.

About Allegro Ophthalmics, LLC
Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases. Pre-clinical data suggest that risuteganib (Luminate®), Allegro’s lead investigational anti-integrin compound in retina, simultaneously acts on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as DME and intermediate dry AMD. Risuteganib successfully completed two Phase 2 DME studies and is currently being evaluated in a U.S. Phase 2 intermediate dry AMD study. Expanding its anti-integrin portfolio, Allegro has developed ALG-1007, an anti-integrin drug candidate for topical use in DED. ALG-1007 has successfully completed an ex-U.S. proof-of-concept study in humans, and is currently being evaluated in a larger ex-U.S. Phase 2 study. For more information, visit www.allegroeye.com.

Luminate® is a registered trademark of Allegro Ophthalmics, LLC.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190430005325/en/

CONTACT: MEDIA CONTACT:

Michele Gray

Gray Communications, LLC

(917) 449-9250

michele_gray@me.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS OPTICAL PHARMACEUTICAL RESEARCH OTHER SCIENCE FDA SCIENCE GENERAL HEALTH

SOURCE: Allegro Ophthalmics

Copyright Business Wire 2019.

PUB: 04/30/2019 11:00 AM/DISC: 04/30/2019 11:00 AM

http://www.businesswire.com/news/home/20190430005325/en

All contents © copyright 2019 The Associated Press.All rights reserved.